AI Terminal

MODULE: AI_ANALYST

Interactive Q&A, Risk Assessment, Summarization

MODULE: DATA_EXTRACT

Excel Export, XBRL Parsing, Table Digitization

MODULE: PEER_COMP

Sector Benchmarking, Sentiment Analysis

SYSTEM ACCESS LOCKED

Authenticate / Register Log In

Biohit Oyj

Board/Management Information • Jun 15, 2023

3304_rns_2023-06-15_b00b79bf-aaf7-41d3-9ce6-a52ebae632c4.pdf

Board/Management Information

Open in Viewer

Opens in native device viewer

Constitutive meeting of Biohit Oyj's Board of Directors

Biohit Oyj, Other information disclosed according to the rules of the Exchange, June 15, 2023 at 2:00 pm local time (EEST)

Biohit Oyj's Board of Directors has in its meeting on June 14 elected Ph.D (Jur.), LL.M. Vesa Silaskivi as the Chairman of the Board of Directors.

Silaskivi is an experienced board professional and thus a valuable contributor to the company's growth.

Additional information:

CEO Jussi Hahtela, Biohit Oyj

tel. +358 9 773 861

[email protected] www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is "Innovating for Health" – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com